Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Looking Past Aduhelm, Biogen Puts Pipeline On Display

Data Expected From Six Trials For Five Drugs Through 2022

Executive Summary

In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.

You may also be interested in...



Biogen's Singhal On Stepping Into R&D Leadership Shoes Amid Aduhelm Controversy

Priya Singhal took over as Biogen's top R&D leader on an interim basis after Al Sandrock’s unexpected retirement. "I understand that this is a challenging time," she told Scrip.

Eisai Bets On Accelerated Approval For Biogen-Partnered Lecanemab

Following Biogen’s lead with Aduhelm, the first disease-modifying Alzheimer’s therapy approved in the US, Eisai began a rolling BLA submission for lecanemab (BAN2401) ahead of next year’s Phase III results. 

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel